radionuclides highly cytotoxic considerable treatment cancer particularly interesting approach radioimmunotherapy antibody conjugates difficult exploit clinically short radionuclides low production capability limited source materials developed novel technology based rate nuclide 227th exemplified using monoclonal antibody rituximab vitro radioimmunoconjugate killed lymphoma cells becquerel milliliter levels single injection induced complete tumor regression NUMBER nude mice bearing macroscopic mm3 human xenografts becquerel gram levels apparent toxicity therapy significantly effective control radioimmunoconjugate standard radioimmunoconjugate cd20 thorium227 based constructs provide novel approach targeted therapy wide variety cancers alpha emitting alpha emitting half life low dose alpha particle emitting 227th rituximab NUMBER NUMBER b lymphoma 227th rituximab 227th trastuzumab beta emitting lymphoma90y tiuxetan ibritumomab bq ml bq g